{"nctId":"NCT00068601","briefTitle":"S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer","startDateStruct":{"date":"2003-10"},"conditions":["Breast Cancer","Infertility","Menopausal Symptoms"],"count":257,"armGroups":[{"label":"Standard Chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cyclophosphamide"]},{"label":"Chemotherapy Plus Goserelin","type":"EXPERIMENTAL","interventionNames":["Drug: cyclophosphamide","Drug: goserelin acetate"]}],"interventions":[{"name":"cyclophosphamide","otherNames":[]},{"name":"goserelin acetate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n\n  * Stage I-IIIA\n  * Operable disease\n* Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative\n* Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1 of the following criteria:\n\n  * 3-month/4-course anthracycline-based regimen\n  * 6- to 8-month/course anthracycline-based regimen\n  * 6- to 8-month/course non-anthracycline-based regimen\n* Hormone receptor status:\n\n  * Estrogen receptor negative\n  * Progesterone receptor negative\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 to 49\n\nSex\n\n* Female\n\nMenopausal status\n\n* Premenopausal\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective barrier contraception\n* No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* See Disease Characteristics\n* No prior cytotoxic chemotherapy\n\nEndocrine therapy\n\n* No other concurrent hormonal therapy\n\nRadiotherapy\n\n* Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* Concurrent participation in other therapeutic clinical trials, including SWOG-S0221, allowed","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Premature Ovarian Failure at 2 Years","description":"Ovarian failure at two years is defined as amenorrhea (absence of menstrual bleeding) for the preceding six months AND the presence of follicle-stimulating hormone (FSH) in the post-menopausal range.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Ovarian Dysfunction at 2 Years","description":"Ovarian dysfunction is defined as amenorrhea for the preceding three months and the presence of FSH, estradiol and/or inhibin B levels in the postmenopausal range.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ovarian Reserve at 1 and 2 Years","description":"Measurements of ovarian reserve will consist of \"Day 2 - 4\" levels of FSH, estradiol and inhibin B during Month 12/13 and Month 24/25 (or if amenorrheic, anytime during Month 12/13 and Month 24/25).","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Rate of Ovarian Dysfunction at 1 Year","description":"Ovarian dysfunction is defined as amenorrhea for the preceding three months and the presence of FSH, estradiol and/or inhibin B levels in the postmenopausal range.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":111},"commonTop":["Hot flashes/flushes","Pain - Head/headache","Sweating (diaphoresis)","Mood alteration - depression","Mood alteration - anxiety"]}}}